D. Boral Capital lowered the firm’s price target on Nano-X Imaging (NNOX) to $15 from $23 and keeps a Buy rating on the shares following the Q4 report. The firm reduced its market penetration assumptions for the next few years given the time required for market build-out. Nano-X is strengthening its commercial outlook, but broader adoption will depend on clinical validation, market penetration strategies, and regulatory approvals across various regions, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNOX:
- Nano-X Imaging Reports Q4 2024 Financial Results and Regulatory Milestones
- Nano-X Imaging reports Q4 non-GAAP EPS (17c) vs. (18c) last year
- Options Volatility and Implied Earnings Moves Today, March 31, 2025
- Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025
- Largest borrow rate increases among liquid names